SCHEMBL24329996

SCHEMBL24329996

CN(CCNC(=O)OC(C)(C)C)Cc1ccc(Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 4/20 0.48
SIGMAR1 Q99720 4/20 0.48
CTSS P25774 1/20 0.45
CTSK P43235 1/20 0.45
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MEN1 O00255 1/20 0.44
PYCR1 P32322 1/20 0.43
ACKR3 P25106 1/20 0.43
FPR3 P25089 5/20 0.43
FPR2 P25090 5/20 0.43
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
AKT1 P31749 1/20 0.42
NPC1 O15118 1/20 0.42
RECQL P46063 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31687500 0.92 SIGMAR1 (0.58) TMEM97SIGMAR1KMT2AMEN1ACKR3
SCHEMBL1459336 0.86 SIGMAR1 (0.55) TMEM97SIGMAR1CTSSKMT2AMEN1
SCHEMBL29066264 0.81 CKS1B (0.49) CTSSCTSKKMT2AMEN1FPR3
SCHEMBL1065312 0.80 CA2 (0.55) CTSSCTSKFPR3FPR2NPC1
SCHEMBL13237 0.80 CA14 (0.47) TMEM97SIGMAR1CTSSCTSKKMT2A
SCHEMBL31687499 0.80 SIGMAR1 (0.58) TMEM97SIGMAR1KMT2AMEN1ACKR3
SCHEMBL3151917 0.80 SIGMAR1 (0.48) TMEM97SIGMAR1ACKR3
SCHEMBL4600182 0.79 SIGMAR1 (0.62) TMEM97SIGMAR1ACKR3
SCHEMBL23616006 0.79 MAPT (0.41) CTSSCTSKFPR3FPR2CKS1B
SCHEMBL31687472 0.79 SIGMAR1 (0.61) TMEM97SIGMAR1ALDH1A1ACKR3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
EP-4228625-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 Therapeutics, Inc. (US) 2023-08-23 EP disclosed
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS CRBN, CDR2, MDM2 TMEM97 1356/4885SIGMAR1 3709/4885CTSS 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.